Omitrope

About Omnitrope®—Clinical Trial Results

Reach higher: Results you expect

  • After 9 months the increase in HSDS and HVSDS was significant when compared to baseline and comparable in both Omnitrope and Genotropin® patients1
BASELINE THROUGH 9 MONTHS1
  BASELINE 9 MONTHS
Mean (SD) Omnitrope
Powder (N=44)		 Genotropin (N=45) Omnitrope
Powder
(N=44)		 Genotropin (N=45)
Height SDS -3.0 (0.7) -3.1 (0.9) -2.3 (0.7) -2.5 (0.7)
Height Velocity SDS -2.4 (1.3) -2.3 (1.1) 6.1 (3.7) 5.4 (3.2)
Height Velocity (cm/year) 3.8 (1.2) 4.0 (0.8) 10.7 (2.6) 10.7 (2.9)
IGF-1 159 (92) 158 (43) 291 (174) 302 (183)
IGFBP-3 3.5 (1.3) 3.5 (1.0) 4.6 (3.0) 4.0 (1.5)

Raising the Bar: Demonstrated Safety

  • A separate 51-patient study data presented to the FDA “…confirmed that Omnitrope has low and acceptable level of immunogenicity”2
15 MONTHS1
Mean (SD) 15 MONTHS
Omnitrope Powder
(N=42)		 Omnitrope Cartridge
(N=44)
Height SDS -2.0 (0.7) -2.2 (0.7)
Height Velocity SDS 3.4 (2.6) 3.2 (2.9)
Height Velocity (cm/year) 8.5 (1.8) 8.6 (2.0)
IGF-1 300 (225) 323 (189)
IGFBP-3 4.6 (1.3) 4.9 (1.4)

The efficacy and safety of Omnitrope were compared with another somatropin approved for growth hormone deficiency (GHD) in pediatric patients. In sequential clinical trials involving a total of 89 GHD children, 44 patients received Omnitrope for injection 5.8 mg/vial and 45 patients received the comparator for 9 months. After 9 months of treatment, patients who had received the somatropin comparator switched to Omnitrope Cartridge. After 15 months of treatment, all patients were switched to Omnitrope Cartridge to collect long-term efficacy and safety data for Omnitrope Cartridge.2

Genotropin is a registered trademark of Pfizer.

Home | Sandoz US | Disclaimer | Privacy Policy | Novartis | Contact Us

Sandoz

Omnitrope® indications and important safety information

Omnitrope is a recombinant human growth hormone indicated for:

  • Pediatric: Treatment of children with growth failure due to growth hormone deficiency (GHD), Prader-Willi Syndrome, Small for Gestational Age, Turner Syndrome, and Idiopathic Short Stature.
  • Adult: Treatment of adults with either adult onset or childhood onset GHD.

Contraindications

  • Acute Critical Illness
  • Children with Prader-Willi Syndrome who are severely obese or have severe respiratory impairment—reports of sudden death
  • Active Malignancy
  • Active Proliferative or Severe Non-Proliferative Diabetic Retinopathy
  • Children with closed epiphyses
  • Known hypersensitivity to somatropin or excipients

Warnings and Precautions

  • Acute Critical Illness: Potential benefit of treatment continuation should be weighed against the potential risk
  • Prader-Willi Syndrome in children: Evaluate for signs of upper airway obstruction and sleep apnea before initiation of treatment. Discontinue treatment if these signs occur
  • Neoplasm: Monitor patients with preexisting tumors for progression or recurrence. Increased risk of a second neoplasm in childhood cancer survivors treated with somatropin–in particular meningiomas in patients treated with radiation to the head for their first neoplasm
  • Impaired Glucose Tolerance and Diabetes Mellitus: May be unmasked. Periodically monitor glucose levels in all patients. Doses of concurrent antihyperglycemic drugs in diabetics may require adjustment
  • Intracranial Hypertension: Exclude preexisting papilledema. May develop and is usually reversible after discontinuation or dose reduction
  • Fluid Retention (i.e., edema, arthralgia, carpal tunnel syndrome, especially in adults): May occur frequently. Reduce dose as necessary
  • Hypopituitarism: Closely monitor other hormone replacement therapies
  • Hypothyroidism: May first become evident or worsen
  • Slipped Capital Femoral Epiphysis: May develop. Evaluate children with the onset of a limp or hip/knee pain
  • Progression of Preexisting Scoliosis: May develop
  • Otitis Media and Cardiovascular Disorders in Turner syndrome: Patients with Turner syndrome should be evaluated for otitis media and other ear disorders and monitored for cardiovascular disorders
  • Pancreatitis: Consider pancreatitis in patients with persistent severe abdominal pain, especially children
  • Adverse events and death associated with benzyl alcohol: Formulations containing benzyl alcohol (5 mg/1.5 mL Omnitrope Cartridges and the Bacteriostatic Water for Injection diluent for the Omnitrope 5.8 mg/vial) should not be used in premature babies or neonates. Consider the combined daily metabolic load of benzyl alcohol from all sources

Adverse Reactions

Other common somatropin-related adverse reactions include injection site reactions/rashes and lipoatrophy and headaches.

Drug Interactions

  • 11β-Hydroxysteroid Dehydrogenase Type 1: May require the initiation of glucocorticoid replacement therapy. Patients treated with glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in their maintenance doses
  • Pharmacologic Glucocorticoid Therapy and Supraphysiologic Glucocorticoid Treatment: Should be carefully adjusted
  • Cytochrome P450-Metabolized Drugs: Monitor carefully if used with somatropin
  • Oral Estrogen: Larger doses of somatropin may be required in women
  • Insulin and/or Oral Hypoglycemic Agents: May require adjustment

Use In Specific Populations

Pregnancy — Pregnancy Category B

Animal reproduction studies have not been conducted with Omnitrope. It is not known whether Omnitrope can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity.

Nursing Mothers

It is not known whether Omnitrope is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Omnitrope is administered to a nursing woman.

Geriatric Use

The safety and effectiveness of Omnitrope in patients aged 65 and over have not been evaluated in clinical studies. Elderly patients may be more sensitive to the action of somatropin, and therefore may be more prone to develop adverse reactions. A lower starting dose and smaller dose increments should be considered for older patients.

To report Suspected Adverse Reactions, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

© 2011 Sandoz Inc.
a Novartis company